Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Acquired by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC raised its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 10.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 793,300 shares of the company's stock after purchasing an additional 76,959 shares during the period. Establishment Labs accounts for 1.9% of Rice Hall James & Associates LLC's portfolio, making the stock its 10th largest position. Rice Hall James & Associates LLC owned about 2.84% of Establishment Labs worth $34,326,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of ESTA. Capital Research Global Investors acquired a new stake in shares of Establishment Labs during the 1st quarter worth $45,888,000. William Blair Investment Management LLC raised its holdings in shares of Establishment Labs by 14.5% in the 2nd quarter. William Blair Investment Management LLC now owns 481,572 shares of the company's stock worth $21,883,000 after purchasing an additional 60,848 shares during the period. Bamco Inc. NY lifted its stake in shares of Establishment Labs by 28.4% in the 1st quarter. Bamco Inc. NY now owns 429,775 shares of the company's stock valued at $21,876,000 after purchasing an additional 95,000 shares in the last quarter. Sofinnova Investments Inc. grew its holdings in shares of Establishment Labs by 204.1% during the 2nd quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company's stock worth $19,505,000 after purchasing an additional 288,082 shares during the period. Finally, First Turn Management LLC acquired a new stake in Establishment Labs during the 2nd quarter worth approximately $16,812,000. Hedge funds and other institutional investors own 72.91% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Establishment Labs from $61.00 to $50.00 and set an "overweight" rating for the company in a research note on Wednesday, August 7th. Citigroup upped their price objective on shares of Establishment Labs from $45.00 to $50.00 and gave the company a "neutral" rating in a research report on Tuesday, October 1st. BTIG Research raised their price objective on shares of Establishment Labs from $62.00 to $65.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Finally, Stephens restated an "overweight" rating and issued a $68.00 target price on shares of Establishment Labs in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Establishment Labs has an average rating of "Moderate Buy" and a consensus price target of $58.83.

Establishment Labs Stock Performance

ESTA stock traded up $2.33 during trading on Friday, hitting $45.42. 330,789 shares of the company's stock traded hands, compared to its average volume of 374,295. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -14.63 and a beta of 1.20. Establishment Labs Holdings Inc. has a 52 week low of $16.96 and a 52 week high of $60.12. The stock has a fifty day moving average price of $43.20 and a two-hundred day moving average price of $46.05. The company has a quick ratio of 2.91, a current ratio of 4.44 and a debt-to-equity ratio of 4.30.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.11). The company had revenue of $44.12 million during the quarter, compared to the consensus estimate of $43.10 million. Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. The company's revenue for the quarter was down 9.2% on a year-over-year basis. During the same period last year, the business posted ($0.65) EPS. As a group, equities analysts anticipate that Establishment Labs Holdings Inc. will post -2.27 EPS for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.